Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma
June 16th 2025, 4:38pm
European Hematology Association Congress
Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
June 16th 2025, 3:18pm
European Hematology Association Congress
Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.
Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL
June 15th 2025, 5:47pm
European Hematology Association Congress
The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.
Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL
June 15th 2025, 5:38pm
European Hematology Association Congress
Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.
Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL
June 15th 2025, 2:20pm
European Hematology Association Congress
The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.
BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL
June 15th 2025, 2:04pm
European Hematology Association Congress
BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.
Dr Scarfò on Updated Safety Data With BGB-16673 in Relapsed/Refractory CLL/SLL
June 15th 2025, 1:15pm
European Hematology Association Congress
Lydia Scarfò, MD, discusses long-term data with BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma
June 15th 2025, 12:50pm
European Hematology Association Congress
Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.
Early Daratumumab in Patients With Myeloma Experiencing MRD Relapse Delays Clinical Progression
June 15th 2025, 1:21am
European Hematology Association Congress
PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.
Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
June 14th 2025, 7:53pm
European Hematology Association Congress
Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.
IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma
June 14th 2025, 7:43pm
European Hematology Association Congress
The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.
Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML
June 14th 2025, 6:43pm
European Hematology Association Congress
Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.
Talquetamab/Cetrelimab Leads to Deep, Durable Responses in R/R Multiple Myeloma
June 14th 2025, 6:30pm
European Hematology Association Congress
Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.
Dr Curtis on Cyclophosphamide GVHD Prophylaxis in Matched Donor Transplant
June 14th 2025, 4:40pm
European Hematology Association Congress
David Curtis, MBBS, PhD, FRACP, FRCPA, discusses the use of post-transplant cyclophosphamide GVHD prophylaxis in matched donor peripheral blood SCT.
Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL
June 14th 2025, 11:40am
European Hematology Association Congress
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.
Real-World Data Confirm Efficacy of Axi-Cel Across Patient-Related Factors in R/R LBCL
June 13th 2025, 8:19pm
European Hematology Association Congress
Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.
Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL
June 13th 2025, 8:10pm
European Hematology Association Congress
Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.
Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase
June 13th 2025, 8:05pm
European Hematology Association Congress
ASC4START data support potential for asciminib to be standard of care for newly diagnosed chronic myeloid leukemia in chronic phase.
ESAs or Danazol Plus Ruxolitinib Produce Comparable Spleen and Symptom Response Rates in Myelofibrosis With Anemia
June 13th 2025, 7:59pm
European Hematology Association Congress
ESAs or danazol in combination with ruxolitinib displayed similar spleen and symptom outcomes in myelofibrosis with anemia.
JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL
June 13th 2025, 7:47pm
European Hematology Association Congress
JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.